tbuckley/cabot-search huggingface dataset:
ETIOLOGY OF PULMONARY PHTHISIS.
Journal: JAMA (1889)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
GROWTH HORMONE
Journal: JAMA (1961)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
AMA, Joint Commission Urge Physicians Become Part of Solution to Family Violence Epidemic
Authors: Teri Randall
Journal: JAMA (1991)

THE AMERICAN MEDICAL Association (AMA) is urging all physicians to help stop the epidemic of family violence that has reached staggering proportions in the United States. Recently, the Centers for Disease Control, Atlanta, Ga, has designated interpersonal violence as a major public health problem that rivals cancer and heart disease in terms of loss of life and cost to society. Physicians in all specialties are already treating the consequences of domestic violence, sexual abuse, and child and elder abuse. Now the AMA is asking physicians to be aware that violence may be a cause of these injuries and to inform their patients (who are victims) of resources that can help them. To heighten physician awareness of this major health problem, and to increase knowledge regarding its diagnosis, treatment, and prevention, the AMA specifically has launched the National Campaign Against Family Violence. Details of the campaign were revealed in a press
Polymer-fume fever. An elusive diagnosis
Authors: N. Williams
Journal: JAMA (1972)

Polymer-fume fever, which is characterized by a tight, gripping sensation in the chest associated with shivering, sore throat, pyrexia, and weakness, is rarely reported in the literature. It follows exposure to the pyrolysis products of polytetrafluoroethylene (PTFE) during heating or machining the polymer, or contamination of cigarettes and pipes. The patient described here suffered more than 40 attacks during a nine-month period, as a result of contamination of cigarettes. The cause of the fever was not recognized for a long time. Lassitude persisted for several months after the last episode, but no evidence has been found of any permanent ill effects. Polymer-fume fever should always be included in textbook lists of causes of fever of unknown origin.
Children at Risk From Ozone Air Pollution— United States, 1991-1993
Journal: JAMA (1995)

A national health objective for the year 2000 is to reduce exposure to air pollutants so that at least 85% of persons reside in counties that meet Environmental Protection Agency (EPA) standards (objective 11.5) (1). Ozone, the principle component of summer smog, is the most pervasive air pollutant in the United States. The risks associated with ozone and other air pollutants are especially increased for children and adults with asthma (2); however, children with no underlying pulmonary diseases also are at risk for adverse health effects associated with these pollutants (3). In addition, because children of racial/ethnic minorities are more likely to reside in areas with higher air pollution levels, they may be exposed to higher levels of ozone (4). This report presents the findings of an analysis by the American Lung Association (ALA) to characterize pediatric populations potentially at risk for adverse health effects from exposure to ozone air pollution in the United States during 1991-1993.
<i>Announcement:</i> National Stroke Awareness Month — May 2017
Journal: MMWR Morbidity and Mortality Weekly Report (2017)

May is National Stroke Awareness Month, an observance that highlights the importance of knowing the signs and symptoms of stroke and encourages persons to act FAST (Face drooping, Arm weakness, Speech difficulty, Time to call 9-1-1) if someone is having a stroke.Stroke is the fifth leading cause of death in the United States and a leading cause of severe disability (1,2).In the United States, one person dies from stroke approximately every 4 minutes (2).Stroke is preventable and largely treatable.Yet, a recent CDC report notes that the age-adjusted death rate for stroke slightly increased from 36.5 deaths per 100,000 persons in the United States in 2014 to 37.6 in 2015 (1).Approximately 60% of persons who die from stroke are women, and women tend to have worse functional outcomes after experiencing a stroke (3).CDC urges everyone to learn the warning signs of stroke and take action to reduce their risk.Living a healthy lifestyle (e.g., being physically active, eating more fruits and vegetables and foods low in sodium and salt, maintaining a healthy weight, and avoiding smoking) can reduce the chances of having a stroke.Properly managing certain medical conditions (e.g., high blood pressure, high cholesterol, heart disease, and diabetes) also can lower the risk.CDC promotes stroke prevention through several initiatives.The Million Hearts initiative, co-led by CDC and the Centers for Medicare & Medicaid Services, works to prevent stroke.The Paul Coverdell National Acute Stroke Program (https:// www.cdc.gov/dhdsp/programs/stroke_registry.htm)funds state health departments to collect and use data to ensure highquality, statewide systems of care to treat stroke.Additional information regarding stroke prevention is available at https:// www.cdc.gov/stroke/.
Psychiatric morbidity in long-term renal transplant recipients and patients undergoing hemodialysis. A comparative study
Authors: T. P. Kalman
Journal: JAMA (1983)

This study assessed and compared psychiatric morbidity in long-term (five years or longer) renal transplant recipients and patients undergoing hemodialysis. Fifty-seven of 98 transplant recipients and 44 of 89 patients undergoing dialysis returned questionnaires designed to collect demographic information and to detect psychiatric morbidity. The two groups differed significantly only in that the patients undergoing dialysis were both older and medically sicker than the transplant recipients. Forty-six percent of the transplant group and 48% of the dialysis group could be identified as psychiatrically impaired either by their scores on the General Health Questionnaire or by a history of prior psychiatric treatment. The finding of nearly equivalent psychiatric morbidity in these two groups does not support the often-held notions about psychological advantages of transplantation over dialysis. We conclude that psychiatric morbidity in patients with chronic renal failure is high and appears not to be related to the choice of treatment. (<i>JAMA</i>1983;250:55-58)
Erratum
Journal: JNCI Journal of the National Cancer Institute (1976)

In “Mouse Skin Assay of Condensate From Smoking Products Other Than Tobacco” by Peter Bernfeld and Freddy Homburger, the following corrections should be made: Page 743, column 2, line I should read “each experiment by adding up the following figures for” (not “SC's of the two constituents was always low and iowest”); page 744, column 1, line 1 should read “SC's of the two constituents was always low and lowest” (not “each experiment by adding up the following figures for”).
Reverce: Randomized phase II study of regorafenib followed by cetuximab versus the reverse sequence for metastatic colorectal cancer patients previously treated with fluoropyrimidine, oxaliplatin, and irinotecan.
Authors: Kohei Shitara, Takeharu Yamanaka, Tadamichi Denda, Yasushi Tsuji, Katsunori Shinozaki, Yoshito Komatsu, Yoshimitsu Kobayashi, Junji Furuse, Hiroyuki Okuda, Masako Asayama, Kohei Akiyoshi, Yoshinori Kagawa, Takeshi Kato, Eiji Oki, Takashi Ando, Yasuo Ohashi, Takayuki Yoshino
Journal: Journal of Clinical Oncology (2018)

557 Background: The optimal treatment sequence in current standard care for patients (pts) with anti-EGFR antibodies-naïve metastatic colorectal cancer (mCRC) is cetuximab (C) followed by regorafenib (R). The objective of this randomized phase II trial is to evaluate efficacy and safety of the therapeutic sequence of R followed by C compared with that of C followed by R for mCRC pts. Methods: Pts with KRAS exon 2 wild-type mCRC after failure of fluoropyrimidine, oxaliplatin, and irinotecan were randomized to receive sequential treatment with R followed by C ± irinotecan (R-C arm) or reverse sequence (C ± irinotecan followed by R; C-R arm). The primary endpoint was OS. Key secondary endpoints included PFS with initial treatment (PFS1), PFS with second treatment (PFS2), safety, and QOL. The exploratory endpoint was serial biomarker analyses including oncogenic alterations from ctDNA or multiple serum proteins. Results: Between November 2013 and September 2016, 101 pts (51 in the R-C arm and 50 in the C-R arm) were randomized and eligible for efficacy analysis. Baseline characteristics were well-balanced in both arms. Bevacizumab had been previously administered in 96% and 98% pts in R-C and C-R, respectively. Sequential treatment was succeeded in 86% pts in both arms. After a median follow-up of 29.0 months with 81 death events, median OS in R-C and C-R were 17.4 and 11.6 months, respectively (stratified logrank P = 0.0293), with a hazard ratio (HR) of 0.61 for OS (95% CI, 0.39–0.96). HR for PFS1 (R in R-C versus C in C-R) was 0.97 (95% CI, 0.61–1.54), whereas that for PFS2 (C in R-C versus R in C-R) was 0.29 (95% CI, 0.17–0.50). No unexpected safety signals were observed in both arms. OS results in RAS/RAF wild type populations with ctDNA analysis at study entry (n = 86) were similar to those of overall population. Conclusions: This was the first randomized study to compare the two therapeutic sequences of R and C for mCRC, suggesting R followed by C is the preferred sequence. Comparable PFS1 and remarkable PFS2 improvement may lead to a longer OS in R-C sequence. The results of detailed biomarker analysis would be also reported. Clinical trial information: UMIN000011294.
CORMED
Authors: S. Satya-Murti
Journal: JAMA (1991)

The Health Care Financing Administration (HCFA) mandates that only those insurance claims with a three- to five-digit diagnostic<i>ICD</i>code (<i>International Classification of Diseases, Ninth Revision, Clinical Modification</i>) will be considered for reimbursement. Among the rewards for not following the HCFA imperative are denial of payment and duplication of paperwork. Matching an<i>ICD</i>code to a patient's clinical presentation is often time-consuming and at times inexact. Several specialty-specific publications, courses, and software packages have cropped up recently to ease the coding process. Corley Medical Systems has put out a software program with the purpose of aiding access to<i>ICD</i>codes. It contains all of the neurological diagnostic codes, revised and updated to January 1990. A companion hard-copy publication of the same diagnostic codes has been recently published, and updated, by the American Academy of Neurology. The vendor will be putting out an expanded version soon. That will contain codes applicable
Occurrence of Lymphoma in Patients with Longstanding Hyperthyroidism
Journal: JAMA (1963)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Questions, Answers, Etc.
Journal: JAMA (1899)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Disparities in Secondhand Smoke Exposure—United States, 1988-1994 and 1999-2004
Journal: JAMA (2008)

No level of exposure to secondhand smoke (SHS) is safe. Breathing SHS can cause heart disease and lung cancer in nonsmoking adults and increases the risk for sudden infant death syndrome, acute respiratory infections, middle-ear disease, and exacerbation of asthma in children. In the United States, exposure to SHS declined approximately 70% from the late 1980s through 2002, most likely reflecting widespread implementation of laws and policies prohibiting smoking in indoor workplaces and public places during this period. Although the major sources of SHS exposure for nonsmoking adults are the home and workplace, the primary source of SHS exposure for children is the home; therefore, eliminating smoking in workplaces and public places is less likely to reduce children's exposure to SHS. This report examines changes in the prevalence of self-reported SHS exposure at home and changes in any exposure, as measured by serum cotinine (a biologic indicator of SHS exposure), in nonsmoking children, adolescents, and adults. The analysis was conducted using data from the 1988-1994 and 1999-2004 National Health and Nutrition Examination Surveys (NHANES). The results indicated that self-reported SHS exposure at home and SHS exposure as measured by serum cotinine declined significantly (i.e., by 51.2% and 44.7%, respectively) in the U.S. population from 1988-1994 to 1999-2004; however, the decline was smaller for persons aged 4-11 years and 12-19 years. These results underscore the need to continue surveillance of SHS exposure and to focus on strategies to reduce children's SHS exposure.
Atypical FTA-ABS test fluorescence in lupus erythematosus patients
Authors: S. J. Kraus
Journal: JAMA (1970)

An unusual pattern of treponemal fluorescence was found when the flourescent treponemal antibody-absorption (FTA-ABS) test was performed on serum samples from four presumably nonsyphilitic patients with active systemic lupus erythematosus. Instead of the homogeneous fluorescence of the<i>Treponema pallidum</i>organisms seen with serum samples from patients with syphilis, a "beaded" fluorescence was observed. Since the intensity of the atypical fluorescence was comparable to that seen with serum samples from patients with syphilis, if the atypical nature of the fluorescence had not been noted, the test result may have been reported reactive. Such reactive test results could lead to an erroneous diagnosis of syphilis.
National survey of notifications of tuberculosis in England and Wales in 1983. Medical Research Council Tuberculosis and Chest Diseases Unit.
Journal: BMJ (1985)

In a survey of all notifications of tuberculosis in England and Wales for the first six months of 1983 56% of the 3002 newly notified patients who had not been treated before were of white and 37% were of Indian subcontinent (Indian, Pakistani, or Bangladeshi) ethnic origin, findings similar to those of a survey in 1978-9. In the four and a quarter years between the surveys the number of patients notified had declined by 26%, the decline being 28% among those of white and 23% among those of Indian subcontinent ethnic origin. The white patients were on average older than the patients of Indian subcontinent ethnic origin, and a higher proportion of them had respiratory disease (82% compared with 66%). The pulmonary lesions were on average larger and more often bacteriologically positive in the white patients. There were considerable differences between the ethnic groups in the estimated yearly rates of notifications per 100 000 population in England in 1983. The highest rates occurred in the Indian (178) and the Pakistani and Bangladeshi (169) populations and were roughly 25 times the rate in the white population (6 X 9). In the Indian subcontinent ethnic groups the highest rates occurred among those who had arrived in the United Kingdom within the previous five years.
Author's reply
Authors: R D Sturrock
Journal: Annals of the Rheumatic Diseases (1993)

Matters arising/Correction unable to protect the stomach; on the other hand, misoprostol, while affording good protection of both gastric and duodenal mucosa, causes frequent side effects on the intestinal tract.2The conclusions of Taha and Sturrock, however, must be accepted with caution.First of all in a recent paper on the subject they admitted that there was no significant difference in the prevalence of endoscopic abnormalities among patients taking NSAIDs alone or NSAIDs plus gold if the size of such lesions was not taken into consideration.3The relation between the claimed gastroprotective properties of gold and Helicobacter pylon infection is also unproved.The role of H pylori in NSAID gastropathy is still debated, but most studies deny that the microorganism can promote or worsen NSAID injury.2 4The evidence quoted by Taha and Sturrock in favour of an inhibitory effect of gold on H pylori is mostly based on reports which have appeared only as abstracts.Full length papers provide conflicting data.4 5 Taha and Sturrock mention a possible
TRADES-UNIONISM IN MEDICINE.
Journal: JAMA (1901)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Growth reduction vs budget cuts for Medicare: What's in a name?
Authors: M. K. Wynia
Journal: JAMA (1996)

<h3>To the Editor.</h3> —Dr Wright<sup>1</sup>defends proposed Republican changes to Medicare as necessary and good because, he claims, Medicare spending must be reduced to save the Medicare Trust Fund and, moreover, because a reduction in expected spending for Medicare is not actually a budget cut. These assertions are startling. The news that current Republican proposals are urgently needed to save the Medicare Trust Fund is surprising for 2 reasons. First, the trust fund covers Medicare Part A only, while more than half of Republicans' proposed cuts come from Part B. Second, for years the trustees of Medicare have issued little-noted reports explaining when in the future the trust fund could run out of money; now, suddenly, Republicans propose urgent reductions that, incidentally, are at least 3 times larger than necessary to solidify the fund. Wright's distaste for the word<i>cut</i>in the context of Medicare is also intriguing. Previously